Immunological challenges for peptide-based immunotherapy in glioblastoma

TY - JOUR

T1 - Immunological challenges for peptide-based immunotherapy in glioblastoma

AU - Mohme, Malte

AU - Neidert, Marian C

AU - Regli, Luca

AU - Weller, Michael

AU - Martin, Roland

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2014/3

Y1 - 2014/3

N2 - Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.

AB - Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15 months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.

KW - Animals

KW - Antigens, Neoplasm

KW - Cancer Vaccines

KW - Central Nervous System Neoplasms

KW - Clinical Trials as Topic

KW - Glioblastoma

KW - Humans

KW - Immunosuppression

KW - Immunotherapy

KW - Peptides

KW - Journal Article

KW - Review

U2 - 10.1016/j.ctrv.2013.08.008

DO - 10.1016/j.ctrv.2013.08.008

M3 - SCORING: Journal article

C2 - 24064197

VL - 40

SP - 248

EP - 258

JO - CANCER TREAT REV

JF - CANCER TREAT REV

SN - 0305-7372

IS - 2

ER -